肝纤维化和肝硬化逆转的血清学评价

刘天会

doi:10.3969/j.issn.1001-5256.2019.04.003

肝纤维化和肝硬化逆转的血清学评价

DOI: 10.3969/j.issn.1001-5256.2019.04.003

刘天会

首都医科大学附属北京友谊医院肝病中心,肝硬化转化医学北京市重点实验室暨国家消化系统疾病临床医学研究中心

详细信息

中图分类号: R575.2
计量
- 文章访问数: 1525
- HTML全文浏览量: 14
- PDF下载量: 445
- 被引次数: 0
出版历程
- 收稿日期: 2019-01-07
- 出版日期: 2019-04-20

Serological assessment of the reversal of liver fibrosis and cirrhosis

Liu TianHui

Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing Key Laboratory of Translational Medicine in Liver Cirrhosis & National Clinical Research Center for Digestive Diseases

摘要

摘要: 肝纤维化/肝硬化是慢性肝脏疾病的共同病理过程。大量研究已经证实,在经过有效的治疗后,肝纤维化或肝硬化可以得到一定程度的逆转。如何应用简便的血清学指标判断肝纤维化/肝硬化逆转是目前的研究热点,总结了可能用于判断肝纤维化/肝硬化逆转的血清学指标的研究和应用现状。
- 肝硬化 /
- 生物学标记
Abstract: Liver fibrosis/cirrhosis is the common pathological process of most chronic liver diseases. Many studies have confirmed that a certain degree of the reversal of liver fibrosis or cirrhosis can be achieved after effective treatment. How to use simple serological markers to evaluate the reversal of liver fibrosis and cirrhosis is a research hotspot at present. This article summarizes the current status of the research on serological markers for the reversal of liver fibrosis and cirrhosis.
- liver cirrhosis /
- biological markers

HTML全文

参考文献(42)

[1]RAMACHANDRAN P, IREDALE JP, FALLOWFIELD JA. Resolution of liver fibrosis:Basic mechanisms and clinical relevance[J]. Semin Liver Dis, 2015, 35 (2) :119-131.

[2]WONG GL. Non-invasive assessments for liver fibrosis:The crystal ball we long for Non-invasive monitoring of liver fibrosis[J]. J Gastroenterol Hepatol, 2018, 33 (5) :1009-1015.

[3]PINZANI M. Pathophysiology of liver fibrosis[J]. Dig Dis, 2015, 33 (4) :492-497.

[4]IMBERT-BISMUT F, RATZIU V, PIERONI L, et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection:A prospective study[J]. Lancet, 2001, 357 (9262) :1069-1075.

[5]CHENG JY, MA H. Research progress in noninvasive diagnosis of liver fibrosis in patients with chronic liver diseases[J]. J Clin Hepatol, 2014, 30 (2) :178-181. (in Chinese) 程捷瑶, 马红.慢性肝病肝纤维化无创诊断的研究进展[J].临床肝胆病杂志, 2014, 30 (2) :178-181.

[6]POYNARD T, IMBERT-BISMUT F, RATZIU V, et al. Biochemical markers of liver fibrosis in patients infected by hepatitis C virus_longitudinal validation in a randomized trial[J]. J Viral Hepat, 2002, 9 (2) :128-133.

[7]POYNARD T, MUNTEANU M, COLOMBO M, et al. FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC3program[J]. J Hepatol, 2011, 54 (2) :227-235.

[8]PINZANI M. Liver fibrosis in the post-HCV era[J]. Semin Liver Dis, 2015, 35 (2) :157-165.

[9]POYNARD T, MCHUTCHISON J, MANNS M, et al. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin[J]. Hepatology, 2003, 38 (2) :481-492.

[10]POYNARD T, MOUSSALLI J, MUNTEANU M, et al. Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C[J]. J Hepatol, 2013, 59 (4) :675-683.

[11]SHAHEEN AA, MYERS RP. Diagnostic accuracy of the aspartate aminotransferase to platelet ratio index for the prediction of hepatitis C related fibrosis:A systematic review[J]. Hepatology, 2007, 46 (3) :912-921.

[12]DONG M, WU J, YU X, et al. Validation and comparison of seventeen noninvasive models for evaluating liver fibrosis in Chinese hepatitis B patients[J]. Liver Int, 2018, 38 (9) :1562-1570.

[13]KIM WR, BERG T, ASSELAH T, et al. Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients[J]. J Hepatol, 2016, 64 (4) :773-780.

[14]LI Q, CHEN L, ZHOU Y. Changes of FibroScan, APRI, and FIB-4 in chronic hepatitis B patients with significant liver histological changes receiving 3-year entecavir therapy[J]. Clin Exp Med, 2018, 18 (2) :273-282.

[15]STASI C, SALOMONI E, ARENA U, et al. Non-invasive assessment of liver fibrosis in patients with HBV-related chronic liver disease undergoing antiviral treatment:A preliminary study[J]. Eur J Pharmacol, 2017, 806:105-109.

[16]VALLET-PICHARD A, MALLET V, NALPAS B, et al. FIB-4:An inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest[J]. Hepatology, 2007, 46 (1) :32-36.

[17]LI Y, CHEN Y, ZHAO Y, et al. The diagnostic value of the FIB-4 index for staging hepatitis B-related fibrosis:A meta-analysis[J]. PLo S One, 2014, 9 (8) :e105728.

[18]JIN W, LIN Z, XIN Y, et al. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis B-related fibrosis:A leading meta-analysis[J]. BMC Gastroenterol, 2012, 12:14.

[19]DONG XQ, WU Z, ZHAO H, et al. Evaluation and comparison of thirty noninvasive models for diagnosing liver fibrosis in chinese hepatitis B patients[J]. J Viral Hepat, 2018.[Epub ahead of print]

[20]FORNS X, AMPURDANS S, LLOVET JM, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model[J]. Hepatology, 2002, 36 (4 Pt 1) :986-992.

[21]UCAR F, SEZER S, GINIS Z, et al. APRI, the FIB-4 score, and Forn's index have noninvasive diagnostic value for liver fibrosis in patients with chronic hepatitis B[J]. Eur J Gastroenterol Hepatol, 2013, 25 (9) :1076-1081.

[22]KAKISAKA K, SUZUKI Y, FUJIWARA Y, et al. Evaluation of ballooned hepatocytes as a risk factor for future progression of fibrosis in patients with non-alcoholic fatty liver disease[J]. J Gastroenterol, 2018, 53 (12) :1285-1291.

[23]D'AMBROSIO R, DEGASPERI E, AGHEMO A, et al. Serological tests do not predict residual fibrosis in hepatitis C cirrhotics with a sustained virological response to interferon[J]. PLo S One, 2016, 11 (6) :e0155967.

[24]KARSDAL MA, HJULER ST, LUO Y, et al. Assessment of liver fibrosis progression and regression by a serological collagen turnover profile[J]. Am J Physiol Gastrointest Liver Physiol, 2018.[Epub ahead of print]

[25]GUCHOT J, LAUDAT A, LORIA A, et al. Diagnostic accuracy of hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis[J]. Clin Chem, 1996, 42 (4) :558-563.

[26]MCHUTCHISON JG, BLATT LM, de MEDINA M, et al. Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. Consensus Interferon Study Group[J]. J Gastroenterol Hepatol, 2000, 15 (8) :945-951.

[27]PARS A, DEULOFEU R, GIMNEZ A, et al. Serum hyaluronate reflects hepatic fibrogenesis in alcoholic liver disease and is useful as a marker of fibrosis[J]. Hepatology, 1996, 24 (6) :1399-1403.

[28]TAYLOR KR, YAMASAKI K, RADEK KA, et al. Recognition of hyaluronan released in sterile injury involves a unique receptor complex dependent on Toll-like receptor 4, CD44, and MD-2[J]. J Biol Chem, 2007, 282 (25) :18265-18275.

[29]KARSDAL MA, KRARUP H, SAND JM, et al. Review article:The efficacy of biomarkers in chronic fibroproliferative diseases-early diagnosis and prognosis, with liver fibrosis as an exemplar[J]. Aliment Pharmacol Ther, 2014, 40 (3) :233-249.

[30]ROSENBERG WM, VOELKER M, THIEL R, et al. Serum markers detect the presence of liver fibrosis:A cohort study[J].Gastroenterology, 2004, 127 (6) :1704-1713.

[31]TANWAR S, TREMBLING PM, HOGAN BJ, et al. Noninvasive markers of liver fibrosis:On-treatment changes of serum markers predict the outcome of antifibrotic therapy[J]. Eur J Gastroenterol Hepatol, 2017, 29 (3) :289-296.

[32]DECARIS ML, EMSON CL, LI K, et al. Turnover rates of hepatic collagen and circulating collagen-associated proteins in humans with chronic liver disease[J]. PLo S One, 2015, 10 (4) :e0123311.

[33]NIELSEN MJ, KARSDAL MA, KAZANKOV K, et al. Fibrosis is not just fibrosis-basement membrane modelling and collagen metabolism differs between hepatitis B-and C-induced injury[J]. Aliment Pharmacol Ther, 2016, 44 (11-12) :1242-1252.

[34]DANIELS SJ, LEEMING DJ, ESLAM M, et al. ADAPT:An algorithm incorporating Pro-C3 accurately identifies patients with NAFLD and advanced fibrosis[J]. Hepatology, 2018.[Epub ahead of print]

[35]NIELSEN MJ, VEIDAL SS, KARSDAL MA, et al. Plasma ProC3 (N-terminal type III collagen propeptide) predicts fibrosis progression in patients with chronic hepatitis C[J]. Liver Int, 2015, 35 (2) :429-437.

[36]KARSDAL MA, HENRIKSEN K, NIELSEN MJ, et al. Fibrogenesis assessed by serological type III collagen formation identifies patients with progressive liver fibrosis and responders to a potential antifibrotic therapy[J]. Am J Physiol Gastrointest Liver Physiol, 2016, 311 (6) :g1009-g1017.

[37]RAMACHANDRAN P, IREDALE JP. Macrophages:Central regulators of hepatic fibrogenesis and fibrosis resolution[J]. J Hepatol, 2012, 56 (6) :1417-1419.

[38]de SOUZA-CRUZ S, VICTRIA MB, TARRAG AM, et al.Liver and blood cytokine microenvironment in HCV patients is associated to liver fibrosis score:A proinflammatory cytokine ensemble orchestrated by TNF and tuned by IL-10[J]. BMC Microbiol, 2016, 16:3.

[39]HO CH, CHIEN RN, CHENG PN, et al. Aberrant serum immunoglobulin G glycosylation in chronic hepatitis B is associated with histological liver damage and reversible by antiviral therapy[J]. J Infect Dis, 2015, 211 (1) :115-124.

[40]MARSHALL K, JIN J, ATKINSON C. Natural immunoglobulin M initiates an inflammatory response important for both hepatic ischemia reperfusion injury and regeneration in mice[J]. Hepatology, 2017.[Epub ahead of print]

[41]HARDY T, ZEYBEL M, DAY CP, et al. Plasma DNA methylation:A potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease[J]. Gut, 2017, 66 (7) :1321-1328.

[42]MANN J, REEVES HL, FELDSTEIN AE. Liquid biopsy for liver diseases[J]. Gut, 2018, 67 (12) :2204-2212.

施引文献

资源附件(0)

访问统计